Premium
Successful treatment of a child with T/myeloid acute bilineal leukemia associated with TLX3/BCL11B fusion and 9q deletion
Author(s) -
Oliveira Jennifer L.,
Kumar Riten,
Khan Shakila P.,
Law Mark E.,
EricksonJohnson Michele,
Oliveira Andre M.,
Ketterling Rhett P.,
Dogan Ahmet
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22850
Subject(s) - medicine , blood cancer , myeloid leukemia , myeloid , chemotherapy , leukemia , complete remission , fusion gene , cancer research , oncology , cancer , gene , genetics , biology
Acute bilineal leukemias are rare and are commonly associated with t(9;22) and MLL abnormalities. Herein, we report a pediatric case of bilineal T/myeloid acute leukemia associated with del (9q)(q13q22) and TLX3/BCL11B fusion due to the cryptic t(5;14)(q35;32). FISH studies confirmed the TLX3/BCL11B fusion in both the myeloid and lymphoid blasts, while the 9q deletion was restricted to the lymphoid component. Optimal therapy for such patients remains controversial and it is not clear if they should be treated with ALL or AML‐based chemotherapeutic regimens. Our patient has been in extended remission following ALL‐based chemotherapy and a matched unrelated cord blood transplant. Pediatr Blood Cancer 2011;56:467–469. © 2010 Wiley‐Liss, Inc.